Syndax CEO Disposes of $152,835 in SNDX Stock as Company Posts Strong Clinical Data
Syndax Pharmaceuticals CEO Michael A. Metzger sold 7,412 shares on Feb. 6, 2026 for $20.62 apiece, generating $152,835 in proceeds. The company’s shares have risen 63% over six months and trade near $21.01. Recent corporate disclosures show significant stock grants and option awards to Metzger on Feb. 4, while clinical data and analyst buy ratings …